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Abstract
Introduction
Community pharmacists are well positioned to deliver chronic
kidney  disease  (CKD)  screening  services.  However,  little  is
known about the challenges faced by pharmacists during service
implementation. This study aimed to explore community phar-
macists’ experiences and perceived barriers of implementing a
CKD risk assessment service.
Methods
Data collection was performed by using semistructured, open-
ended interview questions. Pharmacists who had implemented a
CKD screening service in Tasmania, Australia, were eligible to
participate.  A purposeful sampling strategy was used to select
pharmacists, with variation in demographics and pharmacy loca-
tion. A conventional content analysis approach was used to con-
duct the qualitative study. Transcripts were thematically analyzed
by using the NVivo 11 software program. Initially, a list of free
nodes was generated and data were coded exhaustively into relev-
ant nodes. These nodes were then regrouped to form highly con-
ceptualized themes.
 
Results
Five broad themes emerged from the analysis: contextual fit with-
in community pharmacy; perceived scope of pharmacy practice;
customer perception toward disease prevention; CKD – an under-
estimated disease; and remuneration for a beneficial service. Phar-
macists found the CKD service efficient, user-friendly, and of sub-
stantial benefit to their customers. However, several pharmacists
observed that their customers lacked interest in disease prevention,
and had limited understanding of CKD. More importantly, phar-
macists perceived the scope of pharmacy practice to depend sub-
stantially on interprofessional collaboration between pharmacists
and general practitioners, and customer acknowledgment of phar-
macists’ role in disease prevention.
Conclusion
Community pharmacists perceived the CKD service to be worth
incorporating into pharmacy practice. To increase uptake, future
CKD services should aim to improve customer awareness about
CKD before providing risk assessment. Further research investig-
ating strategies to enhance general practitioner involvement in
pharmacist-initiated disease prevention services is also needed.
Introduction
Globally,  more  than  497  million  adults  (aged  ≥20  years)  had
chronic kidney disease (CKD) in 2010 (1). In Australia, at the end
of 2015, the number of patients receiving renal replacement ther-
apies (such as dialysis or transplantation) was 968 per million pop-
ulation and rising (2). CKD causes a huge economic burden for
the health care system, and the cost to the Australian government
for treating end-stage kidney disease (ESKD), between 2009 and
2020, is estimated to be between $11.3 billion and $12 billion
AUD (3).
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CKD is common among older Australian adults in primary care
settings; a 2012 study reported abnormal kidney function in 37%
of primary care patients (4). Evidence suggests that early diagnos-
is and management of CKD can reduce the risks of disease pro-
gression and associated cardiovascular disease (CVD) by as much
as 50% (5). Despite this, CKD is often under-recognized, and in
2015 in Australia, 17% of new patients received late referrals to
nephrologists for management of ESKD (2). Additionally, testing
for CKD in Tasmania was suboptimal; serum creatinine measure-
ment was performed during 12 months for only 50.6% of at-risk
individuals and albuminuria was measured in only 9.4% of people
with an estimated glomerular filtration rate (eGFR) of less than 60
mL/min per 1.73 m2 (6). This indicates a large gap in clinical prac-
tice and the need to explore ways to improve early detection of
CKD.
Worldwide,  several  clinical  practice  guidelines  recommend
screening targeted groups of people with established risk factors as
an important strategy for early CKD detection (7). Hence, many
community-based targeted CKD screening programs have been
conducted globally; however, a systematic review evaluating the
effectiveness of these programs reported that most interventions
lacked methodologic rigor and long-term feasibility (8). Instead,
Kidney Health Australia (KHA) identified implementation of tar-
geted “opportunistic” CKD screening within the Australian health
care system as a more feasible approach (9,10).  Opportunistic
screening occurs when a check or test is offered to a person with
no CKD symptoms who has come to the health care system for
other reasons (10).
Currently, in Australia, routine screening for CKD is not prac-
ticed (10). Involving community pharmacists in early CKD detec-
tion could prove beneficial (11). In recent years, the role of phar-
macists  has extended to providing disease prevention services
(12,13), and pharmacy screening for conditions such as diabetes
(14), osteoporosis (15), CVD (16), and atrial fibrillation (17) has
shown potential. Similarly, a community pharmacist–initiated tar-
geted CKD risk assessment service could help to alert  general
practitioners (GPs) of at-risk patients who need further diagnostic
evaluation.
Current literature indicates that risk assessment tools can facilitate
early identification of people at risk of developing CKD. One such
validated tool recommended by KHA is the QKidney risk calculat-
or (18,19), which estimates a person’s 5-year risk of developing
moderate to severe CKD. After a CKD risk assessment service
was developed using this tool, all Tasmanian community pharma-
cies were invited to participate in the CKD risk assessment study.
Consequently, the CKD service was implemented and evaluated at
24 pharmacies (20). Because this was a pilot program, determin-
ing the feasibility of the CKD service and making refinements
were necessary before widespread adoption in the community
pharmacy setting. Then a follow-up qualitative study was conduc-
ted. The aim of this study was to explore pharmacists’ experi-
ences of implementing the CKD service, with a specific objective
of identifying perceived barriers to service implementation.
Methods
Ethical approval
The Tasmanian Social Sciences Human Research Ethics Commit-
tee (H0015669) approved this study.
CKD risk assessment service
Before  implementing  the  CKD  service,  online  training  was
provided for participating pharmacists, and their skills and know-
ledge associated with CKD risk assessment were evaluated (21).
Customer participation for CKD risk assessment was promoted by
displaying a poster in each participating pharmacy; pharmacists
also approached eligible customers directly in the pharmacy. Cus-
tomer eligibility criteria for participation is described in the CKD
risk assessment protocol as shown in the Figure. The online QKid-
ney risk calculator (18,19) was used to identify participants with
≥3% risk; these people were counselled on the results, given edu-
cational materials, and advised to consult their GP for further as-
sessment. After 9 months, participants were followed up and their
laboratory data collected from a pathology provider to determine
the percentage of participants who underwent eGFR and urine al-
bumin creatinine ratio (ACR) measurement. Follow-up data ana-
lysis showed relatively low GP referral uptake (27%), and patho-
logy analysis revealed suboptimal kidney testing in 80% of parti-
cipants with ≥3% risk.
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Figure. Flow diagram for chronic kidney disease risk assessment protocol. 
Abbreviations: BP, blood pressure; CKD, chronic kidney disease; GP, general
practitioner; TIA, transient ischemic attack.
 
Study design and participant selection
Initially, researchers explained the purpose and design of the study
to the pharmacists by mail and/or telephone. Written informed
consent was obtained from all 24 pharmacists before service im-
plementation.  After  the  intervention,  P.G.  telephoned 8  phar-
macists to organize the face-to-face qualitative interview. Parti-
cipants were selected using a purposeful sampling strategy, to
provide variation in demographics and pharmacy location (22). No
pharmacists refused to participate in the qualitative interview.
Data collection
A semistructured, in-depth interview was conducted with indi-
vidual pharmacists at their respective community pharmacies, 4
months after completion of the intervention. Interview questions
were  open-ended  and  directly  related  to  the  study  objectives
(Box). Prompts were also offered to the pharmacists when open-
ended questions elicited little response. All interviews were audio-
recorded and were 15 to 45 minutes long.
Box. Interview Guide for Pharmacists
Would you please describe your daily role as a community pharmacist?
Could you please tell me the demographics of most of the customers that
present to your pharmacy?
Do you have a doctor’s surgery nearby?
What do you think is the current role of community pharmacists in
providing health promotion, risk assessment and screening services?
What did you think about the chronic kidney disease risk assessment
study?
Follow-up questions:
-What did you like most about this service?
-Was there any aspect of this service that you didn’t like?
-Was there any aspect you thought could be improved?
According to you, is the QKidney risk assessment calculator feasible or
useful in a community pharmacy setting?
What was it like to recruit participants for this study?
Follow-up questions:
-What strategy did you use to recruit participants?
-How did you find the recruitment process?
-Did you find it difficult or easy to recruit participants?
-Could you give me examples of a few reasons that participants used for
declining to participate in this study?
How did your participants respond to this risk assessment service? Did
they seem interested?
Did your participants know what chronic kidney disease is before
participation?
Follow-up questions:
-What did your patients think about it?
-What was their reaction?
-Did they come back asking about it?
-Have you received any feedback from participants?
Did you have your own target in mind that you would recruit at least X
number of participants for this study and were you able to accomplish
your target?
Follow-up questions:
-What prevented you from achieving your target?
What do you think stops people in the community from participating in a
pharmacist-led chronic kidney disease risk assessment service?
Do you think people in the community need a chronic kidney disease risk
assessment service?
Have you had any feedback from a general practitioner or a nurse with
regards to the chronic kidney disease risk assessment service?
Overall, would you consider the chronic kidney disease risk assessment
service to be a success? Why?
Follow-up question:
-I am curious to know whether you would be willing to offer this service in
your community pharmacy if you had a choice.
Finally, if there was anything that you would have changed or done
differently when it comes to implementing similar research projects in
your community pharmacy in future, what or how would you do it?
Thank you once again for participating in this study.
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Data analysis
QSR International’s NVivo 11 software program was used to sup-
port each phase of qualitative data analysis. All audio recordings
were transcribed verbatim into Microsoft Word documents by Di-
gitype Australasia (a specialized legal and medico-legal transcrip-
tion service) or P.G., and imported into NVivo. A conventional
approach for content analysis was used to perform the qualitative
research (23). In this type of analysis, the use of preconceived cat-
egories or theoretical perspectives is avoided, and coding categor-
ies are derived directly from the data (participants’ unique per-
spectives). Hence, this approach was deemed most appropriate and
used to gain further insight into the pharmacists’ experiences of
implementing the CKD service.
The general inductive approach (24) was used to identify themes
in the documents that were relevant to study objectives. Initially, a
list of free nodes (data categories) was generated by studying the
transcripts repeatedly, and document contents were thoroughly
coded into relevant nodes. These nodes were then regrouped and
organized hierarchically into trees to establish highly conceptual-
ized themes. Initial coding of the raw data was performed by P.G.,
with a subsequent discussion with a second author (S.T.Z.)  to
reach an agreement on the themes. These themes were then ap-
plied back to the original data. The research team met again to fur-
ther refine the themes, which were reviewed against the original
transcripts. Feedback from participants on results of the analysis
was not obtained. The consolidated criteria for reporting qualitat-
ive research (COREQ) were followed (25).
Results
Eight pharmacists were interviewed and data saturation was met.
The  Table  summarizes  pharmacist  characteristics.  Five  major
themes emerged from the analysis:  contextual  fit  within com-
munity pharmacy; perceived scope of pharmacy practice; custom-
er perception toward disease prevention; CKD – an underestim-
ated disease; and remuneration for a beneficial service.
Contextual fit within community pharmacy
This theme was defined as the appropriateness of providing the
CKD risk assessment service within the context of community
pharmacy practice, as perceived by the pharmacists. Most phar-
macists in this study agreed that the CKD risk assessment was a
well-designed and straightforward service, which could be incor-
porated into their routine practice.
I thought that it was a good idea as a screening. You know it was
nice and simple to go through with the patients. It didn’t take too
long. (P5)
Additionally, pharmacists identified the online risk assessment cal-
culator as a user-friendly tool. They liked the online calculator’s
minimum data requirement, which could be easily obtained from
participants and provided results immediately.
I think it’s definitely a good tool to have and it doesn’t exactly take
very long, so it’s not like it would take that much time out of your
day to do a quick check. (P4)
Most pharmacists mentioned that customers who underwent risk
assessment appreciated the service.
Any of them that clipped up (were identified with ≥3% risk), they
were  in  the  doctors  straightaway…and  they  thought  that  was
good…it was just really positively received by all the participants.
(P3)
However, several pharmacists mentioned that, given the nature of
a community pharmacy business, it was sometimes challenging to
recruit participants and carry out risk assessment. Being the sole
pharmacist on duty or having a busy pharmacy prohibited phar-
macists from performing risk assessment.
Our time was little bit tricky to squeeze it in. Trying to come out and
approach patients about this service and that was a little bit of a
barrier I guess than trying to fit it between prescriptions. (P2)
Some pharmacists reported that the paperwork required too much
time and thinking, and further suggested streamlining or compu-
terizing the entire process.
I think it could be quite easily streamlined so that it becomes easy
to do but it does need to be a real, simple process for the phar-
macist….(P3)
Several pharmacists found that training staff members to identify
eligible customers, and to recruit and perform the initial stages of
the risk assessment, was a useful way to reduce their burden.
As soon as we started teaching the staff members, you know make
sure that you ask them this, then it became a lot easier. (P4)
Perceived scope of pharmacy practice
As perceived by pharmacists, the continuing scope of pharmacy
practice (especially in providing disease prevention services) was
found to be highly dependent on the interprofessional collabora-
tion between pharmacists and GPs, and on customers’ acknow-
ledgment of the role of pharmacists in disease prevention. Phar-
macists reported difficulty in engaging GPs as a key barrier to the
perceived effectiveness of the CKD service. At the beginning of
the study, several pharmacists and GPs had a brief discussion on
the CKD service. Pharmacists received mixed reactions: some GPs
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had a positive view of risk assessment while others did not act-
ively participate. However, most pharmacists said that they did not
receive any feedback from the GPs, and some wanted to know the
outcome of GP referral. Pharmacists expressed that, although they
can provide such services, having GPs on board was crucial. GPs
were considered the final decision makers in the care of patients;
without their support, pharmacists believed that the scope of the
CKD service was limited.
We did communicate that [CKD service] to them [GPs] briefly but
you know they’re very busy. They didn’t take it on board as a big
deal. (P2)
Several pharmacists felt that their professional standing in disease
prevention was still undervalued, with their customers generally
not perceiving this as a role for pharmacists.
I think this is an area still to be developed. I am not sure that in a
general community our credentials as screening people have been
developed or promoted…to the point for people [to] actually see us
as being preventative provider. (P8)
However, integration of the CKD service with other established
pharmacy services, for which pharmacists have credibility (eg,
medication review and diabetes management), was found to im-
prove service acceptability and uptake.
What I did is your kidney study was there and then diabetes study
we started in the pharmacy, so we linked both together and that
has been better. So the same person, we can sometimes do both
studies. (P1)
To encourage customer participation, some pharmacists used fly-
ers or newsletters (in addition to the promotional poster), and in-
vested more time in directly approaching and explaining the ser-
vice to eligible customers.
We went okay once we started going out and really putting posters
up and that sort of thing. (P4)
Several pharmacists stated that large-scale promotion through the
media could help to create awareness and improve the uptake of
pharmacy services.
It’s probably the fact that we don’t have ads on the radio saying go
into pharmacy for this and the other…that’s the thing that makes
people realize what your scope of business is. (P7)
Customer perception of disease prevention
Pharmacists stated that customers were often unwilling to particip-
ate, mainly due to their lack of interest in disease prevention.
The people who I thought would be good to do really didn’t – they
weren’t interested. They didn’t have time for their health basically.
They weren’t worried enough about it. (P3)
Pharmacists also found it difficult to engage customers for partici-
pation.
A lot of the time they [customers] will come in and they are busy….
So they will be like aw I have only got enough time to get my scripts
while I am here. Even though someone could be doing it while they
were waiting for the script. But they don’t seem to see to both of
them together. They just go nope can’t do it, I don’t have enough
time…. (P6)
CKD – an underestimated disease
Pharmacists frequently noted that limited CKD awareness cam-
paigns might have contributed to the reduced uptake of the CKD
service. Pharmacists perceived CKD to be an important, yet often
ignored, chronic disease in the community. They mentioned that,
compared with other diseases such as diabetes, hypertension, or
CVD, CKD and its screening are not promoted on a large scale
within the community.
I think diabetes screening is actually more prominent simply be-
cause of the fact that there is more funding behind it and Diabetes
Tasmania tends to promote it reasonably well in terms of people
getting screened. So again it’s probably an awareness thing I think
that they have more awareness than kidney function possibly does.
(P8)
Additionally, pharmacists found that their customers had a limited
understanding of CKD and kidney functions.  Because CKD is
asymptomatic, customers believed that their kidneys were fine;
hence, they did not see the need for risk assessment.
They didn’t think it was something you know they needed to look
out or they felt fine at that particular moment, so why would they
worry about what their kidneys were doing? (P7)
Remuneration for a beneficial service
Pharmacists perceived the CKD service to be of substantial bene-
fit to their customers. They found that the service helped to raise
participants’ awareness about the kidneys and improved their un-
derstanding of CKD.
I  think the questions [of CKD service] actually [helped] awaken
people to the possibility that [kidneys] could actually be having in-
fluence  on  their  life.  A  lot  of  people  don’t  necessarily  realize
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that…they are likely to have or develop kidney problems…. I think
knowing…the likelihood of that sort of outcome [CKD] is actually
useful information once they [patients] have realized the import-
ance of it. (P8)
Most pharmacists mentioned that they would like to be remuner-
ated for providing the CKD service, especially if it were to be-
come an essential component of the pharmacy business. One phar-
macist stressed that if the service was funded, then they would be
able to allocate more of their own and their staff’s time to it.
There had to be some sort of remuneration…so it makes it [CKD
service] worth the time…. At the end of the day, we have to run a
business and pay for staff so to be able to prioritize time for those
different jobs you need to have some sort of income for it. (P7)
Discussion
Overall, the community pharmacists believed that the CKD risk
assessment service was worth incorporating into pharmacy prac-
tice. Pharmacists perceived that the service would be of benefit to
their customers and important to raising CKD awareness in the
community.  However,  during  service  implementation,  phar-
macists experienced several challenges; difficulty in engaging GPs
was a crucial barrier to the long-term feasibility of the service. Al-
though interprofessional collaboration between pharmacists and
GPs is vital for complete patient care, overall GP engagement was
minimal, even after initial discussion of the CKD service between
some pharmacists and GPs. One reason could be the extent and
mode of the discussion (26). In Australia, the role of community
pharmacists in providing public health and disease prevention ser-
vices is still developing. A qualitative study of Australian GPs
showed that most did not favor pharmacists’ providing screening
services, as they believed screening to be the role of the GP, and
they lacked confidence in pharmacists’ clinical expertise and com-
petence to perform screening services (26). Conversely, the study
found that GPs were generally supportive of those pharmacy ser-
vices that they found useful in managing patients, such as medica-
tion reviews.
Another barrier to service implementation was the limited custom-
er perception of pharmacists’ scope of practice. A qualitative study
exploring the awareness and views of Australian community phar-
macy practice showed that most customers viewed pharmacists
primarily  as  medication  suppliers  and  had  limited  knowledge
about pharmacy practice (27). Similar findings were reported by
another study conducted in Scotland (28), which additionally re-
ported that customers lacked confidence in pharmacists’ extended
role. However, a systematic review examining customer attitudes
found that they were more receptive to the availability of medi-
cine-related services than health promotion or screening services,
but those who experienced these pharmacy services were highly
satisfied with them (12). In a recent Australian atrial fibrillation
screening study, pharmacists perceived combining screening with
other established services, such as medication reviews, as an al-
ternative approach to improve service uptake (29). Similarly, in
this qualitative study, pharmacists observed an improvement in the
customers’ response to the CKD service when it was integrated
with other professional services.
Previous studies have found that, to improve customer awareness
and participation in pharmacy services, pharmacists need to reas-
sess their daily practice and ensure that they are not just dispens-
ing prescriptions (27,29). Instead, pharmacists should play an act-
ive role by directly approaching customers and explaining avail-
able services, and by using prominent flyers (29). Similarly, phar-
macists in this study found investing more time in explaining the
service to customers, and the use of additional flyers or newslet-
ters, improved the service implementation process.
This study identified limited customer understanding of CKD and
kidneys as a potential barrier to service uptake. A study exploring
how the public decides to undergo health checks for CVD preven-
tion found that the decision depends on their perception of being
vulnerable to the disease and having any symptoms (30). Simil-
arly, lack of symptoms was identified as a barrier to CKD service
uptake. Kidney function can decline by as much as 90% before
symptoms appear (10), and lack of this knowledge puts a person at
increased risk when diagnosis is delayed. Hence, providing cus-
tomers with information on CKD before offering risk assessment
might improve their understanding and make them more receptive
to the service.
Customers and GPs were not interviewed in this study. Exploring
their perceptions of the CKD service may help to identify addi-
tional barriers, and addressing these could help the pharmacists
enhance  service  implementation.  Although  only  a  few  phar-
macists were interviewed in this study, in studies with a relatively
homogenous sample population and narrow objectives, interviews
with as few as 6 subjects are sufficient to reach saturation, with
meaningful themes and valuable interpretation (31).
Overall, pharmacists perceived implementation of the CKD risk
assessment service to be feasible in community pharmacy practice.
However,  because  of  the  importance of  GPs in  treating CKD,
pharmacists need to demonstrate their professional expertise to
GPs, explain the benefits of the CKD service, and establish mutu-
al understanding on the referral method. Next, during training,
pharmacists should be made aware of the strategy of integrating
the CKD service with other established services commonly used
by their pharmacy customers. This has the potential to improve
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customer participation and increase service uptake. Also, phar-
macists should play an active role in promoting and delivering the
CKD service and aim to improve customer awareness about CKD
before offering risk assessment. These strategies may help to im-
prove  the  feasibility  of  the  CKD  risk  assessment  service.
However, future research evaluating these strategies is needed.
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Table
Table. Characteristics of Interviewed Pharmacists
Pharmacist’s No. Age Group (y) Gender
Years Worked as a Community
Pharmacist Pharmacy Locationa No. of Participants Recruited
P1 56–65 Male 11–15 S >30
P2 36–45 Male 5–10 S 10–20
P3 56–65 Female >20 N/NE <10
P4 26–35 Female <5 N/NE >30
P5 36–45 Male 5–10 S <10
P6 26–35 Female <5 S <10
P7 46–55 Female 16–20 NW/WW <10
P8 46–55 Male >20 NW/WW <10
Abbreviations: N/NE north/northeast; NW/WW northwest/western wilderness; S south.
a Location of the pharmacy in the state of Tasmania is described geographically.
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